Below find Oxis references, including information on formoterol turbuhalers and asthma treatment and control.
1. Diette GB, Wu AW, Skinner EA et al. Treatment patterns among adult patients with asthma: factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids. Arch Int Med 1999; 159: 2697-2704.
2. van der Molen T, Postma DS, Turner MO et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997; 52: 535-9.
3. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-11.
4. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999; 13: 988-92.
5. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med 1998; 92: 1017-21.
6. Sill V, Bartuschka B, Villiger B, Ortland C, Domej W. Changes in specific airway resistance (sRAW) in moderate asthma after inhalation of formoterol or salmeterol dry powder formaulations. Pneumologie 1999; 53: 4-9.
7. Seberová E, Hartman P, Veverka J, Terl M, Fiserová J, Bengtsson T, Andersson A: Formoterol given by Turbuhaler had as rapid an onset of action as salbutamol given by pMDI. Am J Respir Crit Care Med 1999; 159: A637.
8. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-9.
9. Thompson PJ, Jenkins C, Ruffin RE, Mitchell CA, Holmes PW. Comparison of the efficacy of formoterol 12 micrograms bd via dry powder inhaler with salmeterol 50 micrograms bd via pressurised metered dose inhaler in moderate to severe asthmatics. Eur Respir J 1998; 12(Suppl 28): 324s.
10. Kemp JP, Chervinsky P, Nelson H. A randomized, double-blind, placebo-controlled, dose-response study with formoterol Turbuhaler. J Allergy Clin Immunol 1997; 99: S329.
11. Tötterman KJ, Huhti L, Sutinen E et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J 1998; 12: 573-9.
12. Lötvall J, Persson G, Larsson P, Mardell C, Rosenborg J. Tolerability of inhaled high doses of formoterol and salbutamol in asthmatic patients maintained on twice daily formoterol 12 micrograms (9 micrograms delivered). Eur Respir J 1997; 10(Suppl 25): 103s.
13. Guhan AR, Cooper S, Lewis S, Tattersfield AE. Systemic effects of formoterol and salmeterol in healthy subjects - a dose response comparison. Eur Respir J 1998; 12(Suppl 28): 323s.
14. Löfdahl CG, Svedmyr N: Formoterol fumarate, a new beta2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 1989; 44: 264-71.
15. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-40.
16. Tönnesen F, Laursen LC, Evald T, Ståhl E, Ibsen TB. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest 1994; 105: 697-700.
17. Nana A, Youngchaiyud P, Maranetra N, Boe J, Löfdahl CG, Selroos O, Ståhl E. Beta2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med 1998; 92: 167-72.
18. Dewar MH, Jamieson A, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir Med 1999; 93: 342-4.
19. Malolepszy J, Böszörmeny Nagy G, Brander R, Larsson P. Formoterol 90 micrograms via Turbuhaler was safe in patients with acute bronchoconstriction. Eur Respir J 1998; 12(Suppl 28): 323s.
20. Tattersfield A, Löfdahl CG, Postma DS et al. On demand treatment: comparison of formoterol and terbutaline in moderate asthma. Am J Respir Crit Care Med 1999; 159: A636.
21. Berggren F, Ekström T. Formoterol was more cost-effective in a modelling study than terbutaline in as needed treatment of patients with moderate asthma. Eur Respir J 1999; 14(Suppl 30): 341s.
22. Postma DS, Löfdahl CG, Tattersfield A et al. Formoterol used on demand improves quality of life in patients with asthma. Am J Respir Crit Care Med 1999; 159(No 3 Pt 2): A760.
23. Ind P, Börszörmenyi Nagy G, Pietinalho A, Shiner R, Villasante C, Brander R, Larsson P. Formoterol 4.5 µg, used as needed via Turbuhaler was as safe and well tolerated as terbutaline 0.5 mg. Eur Respir J 1999; 14(Suppl 30): 148s.
24. Vilsvik JS, Ankerst J, Palmqvist M, Persson G, Schaanning J, Johansson Å. Duration of protection of formoterol against exercise-induced bronchoconstriction during regular treatment with formoterol Turbuhaler bid in adult asthmatics. Am J Respir Crit Care Med 1999; 159(No 3 Pt 2): A858.
25. Rott Z, Böcskei C, Poczi M, Juhasz G, Larsson P, Rosenborg J. On the relative therapeutic index between formoterol Turbuhaler and salbutamol pressurized metered dose (pMDI) inhaler in asthmatic patients. Eur Respir J 1998; 12(Suppl 28): 324s.
26. Lipworth J, Tan S, Devlin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998; 104: 431-8.
27. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001.
28. Tattersfield AE, Postma DS, Barnes PJ et al. Exacerbations of asthma - a descriptive study of 425 exacerbations. Am J Respir Crit Care Med 1999; 160: 594-9.
29. Anderson GP, Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta2-adrenoceptor agonist bronchodilator. Life Sci 1993; 52:2145-60.
30. Grønnerød TA, Hamre HS, Oepen G, Von Berg A. Protective effect of single doses of formoterol Turbuhaler 4.5 µg and 9 µg in children with exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1999;159(No 3 Pt 2):A858.
31. Juniper EF, Svensson K, O'Byrne PM, Barnes PJ, Bauer CA, Löfdahl CG, Postma DS, Pauwels RA, Tattersfield AE, Ullman A. Asthma quality of life during 1 year treatment with budesonide with or without formoterol. Eur Resp J 1999;14(5):1038-43.
32. Andersson F, Ståhl E, Barnes P J, Löfdahl C-G, O'Byrne P, Postma D, Pauwels RA, Tattersfield A, Ullman A. The costs and effects of adding formoterol to budesonide: results from the FACET study. Am J Respir Crit Care Med 1999;159(No 3 Pt 2):A762. |
